Memantine Accord

Memantine Hydrochloride, the active ingredient in Memantine Accord, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Accord is an NMDA receptor antagonist used in the management of dementia, particularly Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): helps maintain cognitive function and daily living activities. - Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression. - Alzheimer’s disease (functional decline): may slow the progression of functional loss.

Adverse reactions to Memantine Accord can vary in frequency and severity.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Nausea: mild gastrointestinal upset. - Cough: non‑productive throat irritation.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Hyponatremia: low blood sodium levels. - Allergic reaction: rash, itching, or swelling. - Hallucinations: visual or auditory disturbances. - Severe dizziness: risk of falls. - Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Memantine Accord, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function. - Hepatic disease: use with caution in liver dysfunction. - Concomitant CNS depressants: monitor for additive sedation. - History of seizures: assess risk before initiation. - Pregnancy and breastfeeding: avoid unless benefit outweighs risk. - Store at room temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Memantine Accord may interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - High‑dose anticholinergics: may worsen cognitive impairment.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may reduce absorption, monitor efficacy. - Diuretics: potential for electrolyte imbalance, especially hyponatremia. - Other NMDA antagonists: additive effects on CNS, watch for dizziness. - Anticonvulsants: may alter seizure threshold. - CNS depressants: increased sedation risk.